Testing effectiveness (Phase 2)WithdrawnNCT00550342
What this trial is testing
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Who this might be right for
Focal Segmental Glomerulosclerosis (FSGS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)